QuitVaping behavioral program with texting support to help teens stop vaping
Official title: Behavioral Intervention for Youth to Promote Vaping Cessation
Run by Massachusetts General Hospital · NCT06765291 · Data updated 2026-11-12
This trial will try QuitVaping plus extra texting to see if it helps teens aged 14–18 who vape nicotine quit more than standard education and referral alone.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 14 Years to 19 Years |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | June 18, 2025 |
| Main results expected | February 21, 2029 |
| Study ends | August 31, 2029 |
| Registry record updated | July 7, 2026 |
| Trial ID | NCT06765291 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are 14–18 year olds who have vaped nicotine at least weekly for the past three months and are willing to try to quit or reduce vaping within 30 days, who can read English or Spanish and have a parent/guardian available for the opt-out process.
✕Probably not a fit
Patients who recently used smoking-cessation medications, are unwilling to abstain from other cessation aids, are regular combusted-tobacco smokers, or refuse biochemical testing or participation requirements are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Up to 400 adolescents (ages 14–18) who report at least weekly nicotine vaping will be randomly assigned 1:1 to receive either the QuitVaping intervention plus TIQ texting support or enhanced usual care (education, advice, and TIQ referral). The intervention arm includes 12 brief weekly intervention visits followed by monthly follow-ups through week 36, while all participants complete weekly blinded assessments with biochemical verification of abstinence. Assessments are conducted remotely or in person, and the person conducting outcome assessments is blinded to treatment assignment to minimize bias. The trial tests whether adding the structured QuitVaping program and proactive texting increases nicotine abstinence compared with enhanced usual care.
Why it matters
Potential benefit: If successful, this approach could raise quit rates and reduce nicotine dependence and vaping-related harms among teens.
How similar studies have gone: Text-message cessation programs, including This is Quitting, have shown effectiveness for young people and adults, but intensive behavioral programs specifically targeting adolescent vaping are still an emerging evidence area.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 14-19 inclusive * Self-report of at least weekly nicotine vaping (or use of other non combusted nicotine products, "vaping") for the prior ≥3 months * Self-report of no regular combusted tobacco use (i.e., 5 or more days of smoke smoked tobacco use per week) prior to enrollment and exhaled CO \<10 ppm for those with an in person baseline visit * Report willingness to try to quit or reduce vaping in the next 30 days * Able to understand study procedures and read and write in English or Spanish * Have a parent or legal guardian who is able to participate in the opt out process * Competent and willing to provide written informed consent (if age 18) or assent (if under 18) Exclusion Criteria: * Use of a smoking cessation medication in the prior month (nicotine patch, gum, nasal spray, or inhaler, varenicline, bupropion) * Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study * Unwilling to provide saliva or urine samples * Any condition or situation that would, in the investigator's opinion, make it unlikely that the participant could adhere safely to the study protocol
Where it's running
-
Massachusetts General Hospital, Center for Addiction Medicine, 101 Merrimac Street, Suite 320, Boston, MA 02114
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: A. Eden Evins, MD, MPH — Massachusetts General Hospital
- Study coordinator: A. Eden Evins, MD, MPH
- Email: aeevins@mgh.harvard.edu
- Phone: 617-643-4679
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TUBSIS 2.0 — an online program to help adults reduce or quit smoking and vaping
This program tests whether a free, anonymous, 4-week web-based course using mindfulness, self-compassion, and behavior-change techniques helps German-, English-, and Turkish-speaking adults who smoke or vape reduce or quit tobacco.
-
Social media support groups to help teens and young adults quit vaping
This pilot tries a social-media group program called the Quit the Hit Toolkit to help adolescents and young adults who vape stop using nicotine.
-
Varenicline plus enhanced TMS to help adults quit smoking and vaping
This study tests whether adding active enhanced accelerated transcranial magnetic stimulation (aTMS) to varenicline helps adults 18–65 quit nicotine use more effectively than varenicline with sham stimulation.
-
Varenicline to help adults stop vaping
This trial tests whether the smoking-cessation pill varenicline helps adults who vape daily quit e-cigarettes.
-
Lung health in Canadians who use vaping devices
This project will test new breathing tests, scans, and exercise measures to see if vaping harms the lungs of Canadian adolescents and adults.
-
How people puff IQOS Iluma i vs IQOS 2.4 and how flavors feel
This study tests how exclusive IQOS users puff the newer Iluma i versus the older 2.4, and whether preferred flavor affects puffing and sensory experience.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.